Global Biologics Market -Analysis and Forecast (2017-2025) (Focus on Pipeline Analysis, Product Type, Therapeutic Application, Country Analysis, and Market Dynamics)
The biologics or a biopharmaceutical product means a pharmaceutical semi synthesized from different biological sources. In contrast to completely synthesized drugs, biologics are generally made up of living cells, gene components, sugars, proteins, nucleic acids, tissues, allergenic, and also vaccines. The useful components listed above are isolated from living sources and combined, to cure the disease with minimal side effects. Biologics products often represent the pioneer developments in biotechnology research and often aid medical practitioners in treating a variety of illnesses and conditions which presently have no other treatments available. Other factor such as the ability of biologics to facilitate complete cure of a disease with minimal side effects is boosting the growth of the market.
Geographically, biologics have registered near double digit annual growth rate, whereas, the pharmaceutical drugs registered only single digit annual growth rate, in the past five years. This double digit growth was largely fuelled by the substantial investments of the major pharmaceutical companies, who realized the potential of the market quite early.
The research study comprises of extensive analysis of various factors effecting the global biologics market. The entire market has been estimated and validated through three different approaches namely, by product, by therapeutic areas and by geographical destination. In terms of product, the market has been categorized into monoclonal antibody (mAbs), hormones, growth factors, fusion proteins, cytokines, therapeutic enzymes, vaccines, blood factors, and anticoagulants. The mAbs are the dominating other types in terms of sales and therapeutic enzymes is the highest growing type.
In terms of therapeutic areas the market is segmented into oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases. The market is dominated by oncology related products and infectious diseases related products are expected to grow at the highest rate. In terms of geography, the market was segmented into North America, Europe, Latin America, Middle East, Africa and Rest of the World. In terms of sales, North America currently dominates the other geographical regions whereas, Middle East and Africa together are expected to grow at the highest rate.
The key players which have significant contributions to the biologics market are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Gilead Sciences, Inc., AbbVie Inc., Amgen Inc., Lilly,Bristol-Myers Squibb, Novo Nordisk, Merck KGaA, Allergan, Plc, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, and Biocon Ltd.
The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the global biologics market.
The answers to the following key questions can be derived from this report:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook